The SPEAC Project has developed an initial list of AESI for mpox vaccines. This list was developed by reviewing the existing vaccinia-associated AESI list and Brighton Collaboration (BC) case definitions (CDs) for relevance to LC16 and MVA-BN, and focused reviews of the peer-reviewed and gray literature to inform AESIs relevant to these two vaccines.
SPEAC identifies AESIs based on three criteria: 1) Known association with immunization or a specific vaccine platform, 2) Occurrence during wild-type disease as a result of viral replication and/or immunopathogenesis, and 3) Theoretical association based on animal models. The AESI list for mpox vaccines is derived from mpox disease pathogenesis and vaccine platforms, as well as considerations for manifestations in special populations (children, pregnant women, and immunocompromised hosts, including people living with HIV).
The SPEAC Executive Board welcomes input on this AESI list and will update it periodically. Please share input with the SPEAC and Brighton Collaboration team at bc-coordinator@taskforce.org.
